No. I meant unstable under storage conditions. According to the FDA, there is no pharmacokinetic data on oral NAD in humans. NAD seems to be legal to compound by pharmacies but not recommended in FDAs review of compounded NAD as an answer to a request to use it to treat MS-related fatigue.
ABN wants to sell products and I would not trust them as a source of any information regarding NAD-precursors without verifying that data from other sources. When Alive By Nature were allowed to sell NR they were over the moon for this molecule. When they were dropped by Chromadex (only LEF and Thorne can sell Niagen under their brands) then NMN and NAD were the best things ever.
This is the FDAs decision from 31 march 2017, page 16 of 330:
"We have balanced the criteria described in section II above to evaluate NAD for the 503A Bulks List. After considering the information currently available, a balancing of the criteria weighs against NAD being placed on that list based on the following:
1. NAD is well characterized physically and chemically. However, it is susceptible to substantial degradation when exposed to light, moisture, alkaline pH, or standard room temperatures. Unless multiple compensatory measures to improve its stability are implemented, NAD will likely be unstable when compounded in a capsule, the proposed dosage form.
2. Nonclinical data found in the literature are inadequate to characterize the potential toxicity profile for NAD, particularly for use in a chronic disease such as MS. Similarly, we did not find sufficient clinical data about NAD to evaluate whether it is safe for use in compounded drug products.
3. We found no published information regarding the clinical evaluation of the use of NAD supplementation in the treatment of MS-related fatigue or MS. Therefore, we have insufficient information on the efficacy of NAD to support the nominated use.
4. Information is insufficient to determine the length or extent of historical use of NAD in compounded drug products. Based on internet searches, NAD appears to be available as a compounded product in both topical and intravenous forms. Based on the information the Agency has considered, as described above, a balancing of the four evaluation criteria weighs against NAD being added to the 503A Bulks List.
https://www.fda.gov/...e/ucm553368.pdf
Edited by Fredrik, 09 April 2019 - 08:42 PM.